About us
RusnanoMedInvest (RMI) is Russia’s and Eastern Europe’s largest venture capital company specializing in innovative developments in the field of pharmaceuticals and biotechnology
RMI was created in March 2012. The investor of RMI is RUSNANO, the nanotechnology investment, research and development arm of the Russian Government. The main objectives of RMI are:
- localization of innovative life sciences and pharmaceutical technology in Russia
- creation and accumulation of Russian-originated world-class expertise in the field of venture capital financing in Life Sciences
- stimulating the interest of investors and potential investors in the financing of Russian life sciences ideas, concepts and technologies
All Portfolio
MEDIA CENTER
-
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.